Neumora director granted 80,000 options at $1.86
Neumora Therapeutics director Matthew K. Fust received a grant of stock options covering 80,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Neumora Therapeutics director Matthew K. Fust received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036. All 80,000 shares vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Following this compensation award, Fust holds 80,000 derivative securities directly.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Fust Matthew K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 80,000 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Key Figures
Stock options granted: 80,000 options
Exercise price: $1.86 per share
Expiration date: May 26, 2036
+2 more
5 metrics
Stock options granted
80,000 options
Grant of Stock Option (Right to Buy) to director
Exercise price
$1.86 per share
Conversion or exercise price of granted options
Expiration date
May 26, 2036
Option expiration for 80,000-share grant
Shares underlying options
80,000 shares
Underlying Common Stock tied to granted options
Holdings after transaction
80,000 derivative securities
Total stock options held directly after grant
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price, Annual Meeting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 1.8600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting financial
"immediately prior to the next Annual Meeting following May 27, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
vest financial
"100% of the shares subject to the option vest on the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Neumora (NMRA) director Matthew K. Fust report?
Matthew K. Fust reported receiving a grant of stock options for 80,000 shares of Neumora Common Stock. The options are a compensation award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price in the future.
What is the exercise price of the Neumora (NMRA) stock options granted to Matthew Fust?
The granted stock options have an exercise price of $1.86 per share. This means Fust can buy up to 80,000 Neumora Common Stock shares at $1.86, regardless of the market price, once the options are vested and before they expire.
When do Matthew Fust’s Neumora (NMRA) stock options vest?
All 80,000 stock options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next Annual Meeting after that date. Vesting must occur before the options become exercisable for Neumora shares.
When do the Neumora (NMRA) stock options granted to Matthew Fust expire?
The stock options granted to Matthew Fust expire on May 26, 2036. After this expiration date, any unexercised portion of the 80,000 options can no longer be used to purchase Neumora Common Stock at the $1.86 exercise price.
Is Matthew Fust’s Neumora (NMRA) Form 4 transaction an open-market buy or sale?
The Form 4 shows a grant of stock options as a compensation award, not an open-market trade. The transaction is coded as an acquisition (A) of derivative securities, giving Fust the right to buy shares later instead of immediately purchasing or selling stock.
How many Neumora (NMRA) derivative securities does Matthew Fust hold after this Form 4 transaction?
After this transaction, Matthew Fust holds 80,000 derivative securities in the form of stock options. These options each relate to one share of Neumora Common Stock and are held directly, subject to the vesting schedule and the May 26, 2036 expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates